Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Dr. Davidson Discusses Breast Cancer Chemoprevention

March 23rd 2012

Dr. Nancy Davidson, from the University of Pittsburgh Cancer Institute, Discusses Breast Cancer Chemoprevention

Dr. Chang on Combining HER2 Targeted Therapies

March 22nd 2012

Dr. Jenny Chang, from the Methodist Cancer Center, Discusses Combining HER2 Targeted Therapies

Dr. Borgen on the Negative Effects of Pinkwashing

March 20th 2012

Dr. Patrick Borgen, from the Maimonides Breast Cancer Center, Discusses the Negative Effects of Pinkwashing

Surgical Breast Biopsy Not Overused, Study Suggests

March 19th 2012

Contrary to earlier findings, surgical breast biopsies may not be as overused as previously thought, according to a recent study published in the Journal of the American College of Radiology.

Dr. Tripathy Discusses Breast Cancer Prevention

March 16th 2012

Dr. Debu Tripathy, from the USC Norris Comprehensive Cancer Center, Discusses Breast Cancer Prevention

Emerging Therapies for HER2-Positive and Triple-Negative Breast Cancers

March 16th 2012

Recognition of breast cancer subtypes and research into their underlying biologies is driving the development of new therapies.

Dr. Gralow on Breast Cancer Adjuvant Bisphosphonates

March 16th 2012

Dr. Julie Gralow, from the Seattle Cancer Care Alliance, on Adjuvant Bisphosphonates for Breast Cancer

Immunotherapy Emerges as Promising Strategy in Breast Cancer

March 16th 2012

Next-generation immunotherapy in breast cancer treatment is an active field of scientific exploration with the potential to yield a vaccine.

Dr. Osman on the 29th Miami Breast Cancer Conference

March 15th 2012

Dr. Daniel Osman, the program chair for the Miami Breast Cancer Conference, Discusses the 29th Annual Meeting

Advances in Genomics Mask Complexities

March 15th 2012

Technological advances in genomics have prompted a "sea change" in breast cancer drug development and treatment.

Patients, Surgeons Face Hurdles in Making Breast Cancer Decisions

March 15th 2012

The choice of breast-conserving surgery over mastectomy is often based on fear of recurrence and death rather than clinical evidence.

Four Key Areas Are Focus of ASCO/SABCS Highlights

March 14th 2012

Debu Tripathy, MD, culled the highlights from abstracts presented in 2011 at the ASCO annual meeting in Chicago, Illinois, and at the CCTR-AARC SABCS in Texas.

29th Annual Miami Breast Cancer Conference Opens

March 14th 2012

The impact of molecular and genomic advancements on the treatment of patients with breast cancer will be among the prime topics of discussion.

Miami Breast Cancer Conference Founder Keeps Focus on Future

March 12th 2012

As the Miami Breast Cancer Conference enters its 29th year, Osman continues to organize the gathering and pack the 4-day meeting with faculty speakers.

Dr. Schnabel Discusses the DCIS Recurrence Score

March 9th 2012

Dr. Freya Schnabel from NYU School of Medicine Discusses the DCIS Recurrence Score

Taking a Leap in Cancer Diagnostics: Clarient Enters New Era in Molecular Tumor Testing, Drug Discovery Research

March 9th 2012

Clarient provides more than 350 diagnostic tests to assess and characterize tumors, including tests for BRAF, KRAS, and EGFR gene mutations.

Dr. Harvey Discusses Preventing Breast Cancer

March 8th 2012

Dr. Harold Harvey from Penn State Hershey Cancer Institute Discusses Preventing Breast Cancer

Assay Offers Molecular Analysis of Breast Cancer Risk Recurrence: Interview With Kenneth J. Bloom, MD

March 7th 2012

The options for exploring tumor biology continue to multiply amid technological advances that are making molecular testing options a routine part of oncology treatment.

Dr. Baselga Discusses the BOLERO Breast Cancer Trials

March 5th 2012

Dr. Jose Baselga from Massachusetts General Hospital Discusses the BOLERO Breast Cancer Trials

Targeting HER2: Pertuzumab Puts the Spotlight on Dual Blockade Strategies

March 2nd 2012

Since the discovery of the HER2/neu gene in the late 1970s, aberrations in the HER2 signaling pathway have been implicated in a wide variety of human cancers.